Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Siolta Therapeutics Scoops Up $12M Series C

2024-03-13
SAN CARLOS, CA, Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round.
The round, co-led by SymBiosis and Khosla Ventures, with participation of all existing investors, reflects enthusiasm for Siolta's approach to developing live microbiome-based therapeutics.

Siolta Therapeutics is a clinical-stage biotech company developing defined-consortia live biotherapeutic products that target the core drivers of disease. By leveraging our proprietary Precision Symbiotics Platform™, we have successfully advanced multiple programs into clinical and preclinical development. Our lead program, STMC-103H, is in phase 2 development for the prevention of atopic diseases, including atopic dermatitis, food allergy, and asthma. We are also advancing two preclinical programs, STMC-105 and STMC-106, targeting recurrent bacterial vaginosis and necrotizing enterocolitis indications for which no FDA-approved products exist.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors